This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Jaffe, J. J. Articles by Prusoff, W. H. Search for Related Content PubMed PubMed Citation Articles by Jaffe, J. J. Articles by Prusoff, W. H.

The Effect of 5-Iododeoxyuridine upon the Growth of Some Transplantable Rodent Tumors^*

( Department of Pharmacology, Yale University School of Medicine, New Haven, Conn.)

5-Iododeoxyuridine, an analog of thymidine, when injected in amounts of 100 or 150 mg/kg/day, inhibited by 50 per cent or more the growth of Sarcoma 180 and of lymphomas L1210 and L5178-Y, without evidence of significant host toxicity; however, in these amounts, 5-iododeoxyuridine was completely ineffective as an inhibitor of the growth in rats of Walker carcinosarcoma 256.

Only additive inhibitory effects on the growth of lymphoma L1210 were seen when IUdR was administered to mice in combination with the following antimetabolites: azaserine, 6-azathymine, 6-azauridine, 5-fluorodeoxyuridine, or amethopterin. Less than additive inhibitory effects on the growth of lymphoma L1210 were seen in mice given 5-iododeoxyuridine together with 6-mercaptopurine. Reserpine had no influence on the degree of antitumor activity of a given dose of 5-iododeoxyuridine.

Differences between 5-iododeoxyuridine and the closely related halogenated nucleoside, 5-fluorodeoxyuridine, regarding their metabolic disposition and interactions with other agents are discussed.

^* This investigation was supported by grants C-2817 from the National Cancer Institute and CY-3076 from the National Institutes of Health, U.S. Public Health Service.

Received 5/ 4/60.